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Abstract:		Targeting	 transferrin	 receptor	 1	 (TfR1)	 with	 monoclonal	 antibodies	 is	 a	 promising	therapeutic	strategy	in	cancer	as	tumor	cells	often	overexpress	TfR1	and	show	increased	iron	needs.	We	have	re-engineered	six	anti-human	TfR1	single-chain	variable	fragment	(scFv)	antibodies	into	fully	human	scFv2-Fcγ1	and	IgG1	antibodies.	We	selected	the	more	promising	 candidate	 (H7),	 based	 on	 its	 ability	 to	 inhibit	 TfR1-mediated	 iron-loaded	transferrin	 internalization	 in	 Raji	 cells	 (B-cell	 lymphoma).	 The	H7	 antibody	 displayed	nanomolar	affinity	for	its	target	in	both	formats	(scFv2-Fcγ1	and	IgG1),	but	cross-reacted	with	mouse	TfR1	 only	 in	 the	 scFv2-Fc	 format.	H7	 reduced	 the	 intracellular	 labile	 iron	pool	 and,	 contrary	 to	 what	 has	 been	 observed	 with	 previously	 described	 anti-TfR1	antibodies,	upregulated	TfR1	level	in	Raji	cells.	H7	scFv2-Fc	format	elimination	half-life	was	 similar	 in	 FcRn	 knock-out	 and	 wild	 type	 mice,	 suggesting	 that	 TfR1	 recycling	contributes	 to	 prevent	 H7	 elimination	 in	 vivo.	 In	 vitro,	 H7	 inhibited	 the	 growth	 of	erythroleukemia	 and	 B-cell	 lymphoma	 cell	 lines	 (IC50	 0.1	 µg/mL)	 and	 induced	 their	apoptosis.	Moreover,	the	Im9	B-cell	 lymphoma	cell	 line,	which	is	resistant	to	apoptosis	induced	 by	 rituximab	 (anti-CD20	 antibody),	 was	 sensitive	 to	 H7.	 In	 vivo,	 tumor	regression	was	observed	 in	nude	mice	bearing	ERY-1	 erythroleukemia	 cell	 xenografts	treated	 with	 H7	 through	 a	 mechanism	 that	 involved	 iron	 deprivation	 and	 antibody-dependent	cytotoxic	effector	functions.	Therefore,	targeting	TfR1	using	the	fully	human	anti-TfR1	H7	is	a	promising	tool	for	the	treatment	of	leukemia	and	lymphoma.	
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Introduction	
	Iron	deprivation	is	an	emerging	strategy	in	cancer	therapeutics.	Tumors	have	high	iron	content	 and	 rely	 on	 iron	 for	 their	 growth	 and	 progression.1	 Cancer	 stem	 cells	 also	require	iron	for	their	survival.2,	3	Iron	levels	in	cells	can	be	reduced	with	iron	chelators,4	which	 are	 already	 used	 in	 the	 clinic	 for	 iron	 overload	 disorders,	 or	 with	monoclonal	antibodies	 (mAbs)	 against	 transferrin	 receptor	 1	 (TfR1).	 TfR1	 is	 the	 main	 receptor	responsible	for	the	cell	iron	supply	through	receptor-mediated	internalization	of	serum	Fe3+-loaded	 transferrin	 (holo-Tf).	 Within	 the	 cell,	 Fe3+	 is	 released,	 reduced,	 excluded	from	the	early	endosome	by	divalent	metal	ion	transporter	1	(DMT1),	and	used	for	cell	metabolism.	 Fe3+	 excess	 is	 stored	 in	 ferritin,	while	TfR1	 is	 recycled	 at	 the	 cell	 surface	together	with	iron-free	transferrin	(apo-Tf).5	Several	studies	reported	that	in	vitro,	incubation	of	tumor	cell	lines	with	some	anti-TfR1	mAbs	 decreases	 cell	 viability.	 The	 reasons	 for	 the	 decrease	 of	 cell	 viability	 (cell	 cycle	arrest,	mechanism	of	cell	death,	if	observed)	and	its	intensity	largely	vary	depending	on	the	 cancer	 cell	 type	 (for	 example,	 hematopoietic	 cancer	 cells	 are	more	 sensitive	 than	solid	cancer	cells),	on	the	TfR1	epitope	recognized	by	the	antibody,	and	on	the	antibody	format	 (bivalency	 is	 generally	 required).	 Inhibition	 of	 cell	 viability	 is	 observed	 when	anti-TfR1	 mAbs	 reduce	 the	 cell	 iron	 supply	 through	 competition	 with	 holo-Tf,5-8	 or	inhibition	of	TfR1	internalization,9	or	induction	of	TfR1	degradation.10,	11		We	 have	 recently	 obtained	 six	 rapidly	 internalized	 agonistic	 competitive	 anti-TfR1	single-chain	variable-fragment	(scFv)	antibodies	by	phage	display.12	In	this	monovalent	format,	 the	 F12	 and	 H7	 antibodies	 were	 the	 best	 holo-Tf	 competitors.	 In	 vitro,	 they	
		 5	
inhibited	the	growth	of	B-cell	lymphoma	and	erythroleukemia	cells	(Raji	and	ERY-1	cell	lines,	 respectively),	 and	 their	 efficiency	 increased	 upon	 conversion	 to	 the	 scFv	homodimeric	 format	 (scFv2).	 However,	 we	 found	 that	 in	 nude	 mice	 with	 established	subcutaneous	 (s.c.)	 ERY-1	 erythroleukemia	 cell	 xenografts,	 treatment	 with	 scFv2-F12	significantly	 inhibited	 tumor	 growth,	 but	 tumor	 escape	 occurred.6	 We	 reasoned	 that	because	bivalent	scFv2	antibodies	are	prone	to	rapid	elimination	through	the	kidney	due	to	their	small	size	(50	kD)13,	14	and	because	the	Fc	domain	contributes	to	the	long	serum	persistence	of	immunoglobulins	via	 interaction	with	the	neonatal	Fc	receptor	(FcRn),15	we	 might	 improve	 the	 in	 vivo	 therapeutic	 effect	 observed	 with	 the	 scFv2	 format	 by	converting	these	anti-TfR	scFv	antibodies	to	formats	containing	a	human	Fcγ1	(scFv2-Fc	and	 full	 length	 IgG1,	Figure	1A).	These	 formats	were	 chosen	 to	 improve	 the	antibody	pharmacokinetics	(PK)16	and	to	add	effector	functions	(such	as	antibody-dependent	cell-	mediated	 cytotoxicity	 (ADCC)	 and	 phagocytosis	 (ADCP)),17	 to	 the	 scFv	 intrinsic	inhibitory	potential.	This	 report	 presents	 the	 in	 vitro	 characterization	 of	 the	 reformatted	 anti-TfR1	antibodies	 and	 their	 effects	 on	 hematological	 cancer	 cell	 lines,	 particularly	 of	 H7,	 the	most	efficient	antibody	that	also	displayed	promising	therapeutic	efficacy	in	vivo.	
	
Results		
Antibody	binding	to	TfR1	and	inhibition	of	holo-Tf	internalization		All	 the	 six	 parental	 anti-TfR1	 scFv	 antibodies	 (H7,	 F12,	 C32,	 F2,	 H9,	 G9)	 could	 be	converted	 into	 the	 scFv2-Fc	 and	 IgG1	 antibody	 formats	 (Figure	 1A),	 with	 high	production	 yields	 except	 for	 F12-IgG1.	 The	 initial	 characterization	was	 done	 to	 verify	that	 the	 new	 antibody	 formats	 could	 bind	 to	 TfR1	 and	 inhibit	 TfR1-mediated	 holo-Tf	
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internalization,	like	the	parental	scFv	antibodies.6	The	TfR1-expressing	B-cell	lymphoma	Raji	and	mastocytoma	P815	cell	lines	were	used	to	test	the	binding	to	human	and	mouse	TfR1,	 respectively	 (Figure	1C).	 Among	 the	 scFv2-Fc	 antibodies,	 only	H7,	 F12	 and	C32	also	recognized	mouse	TfR1	(Figure	1C,	upper	panel).	Among	the	IgG1	antibodies,	H7	and	C32	lost	cross-reactivity	to	mouse	TfR1	(Figure	1C,	lower	panel).	All	six	scFv2-Fc	antibodies	 inhibited	 internalization	 of	 500	 nM	Alexa	 488-conjugated	 holo-Tf	 (holo-Tf-A488),	 and	 H7-Fc	 was	 the	 most	 efficient	 with	 70%	 inhibition	 at	 5	 µg/mL	 (50	 nM)	(Figure	 1D	 and	 S1).	 Concerning	 the	 IgG1	 antibodies,	 the	 inhibition	 of	 holo-Tf	internalization	by	G9	and	C32	was	greatly	reduced	compared	with	the	scFv2-Fc	format.	H7-IgG1	was	again	the	most	efficient	with	50%	inhibition	at	5	µg/mL	(33	nM).	Another	anti-TfR1	 mAb	 Ba120	 (mouse	 IgG1),	 which	 shows	 inhibitory	 activity	 in	 leukemia	models,18	had	no	effect.		H7	was	then	chosen	for	more	extensive	characterization	and	comparison	with	Ba120.	To	test	 their	capacity	 to	block	 internalization	of	holo-Tf	at	physiological	concentrations,	5	µg/mL	of	H7-Fc	and	H7-IgG1	(i.e.,	50	nM	and	33	nM,	respectively)	were	mixed	with	10	µM	holo-Tf-A488.	H7-Fc,	but	not	H7-IgG1,	 still	 inhibited	holo-Tf	 internalization	 in	Raji	cells	 (Figure	 2A,	 left	 panel	 and	 right	 panel,	 respectively).	 Surprisingly,	 Ba120	increased	 holo-Tf	 internalization	 of	 more	 than	 50%.	 The	 apparent	 affinity	 constant	(EC50)	 (Figure	2B)	 and	 the	antibody	 concentration	 that	blocked	50%	of	holo-Tf-A488	binding	(used	at	500	nM)	to	human	TfR1	(IC50)	at	4°C	in	Raji	cells	(Figure	2C)	were	then	determined.	H7-Fc,	H7-IgG1	 and	Ba120	displayed	 subnanomolar	 EC50	 values,	 showing	better	 binding	 to	 human	 TfR1	 than	 holo-Tf	 (EC50	 16	 nM)	 in	 the	 same	 conditions.	Alternatively,	 H7-Fc	 and	 H7-IgG1	 KD	 (dissociation	 constant)	 values	 were	 also	determined	 by	 surface	 plasmon	 resonance	 (SPR)	 using	 a	 steady-state	 fitting	 model	
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(Figure	S2).	Similar	KD	(5	nM)	were	found	for	H7-Fc	and	H7-IgG1.	Moreover,	H7-Fc	and	H7-IgG1	 fully	 inhibited	holo-Tf	binding	 to	human	TfR1	 (IC50	of	5	nM),	whereas	Ba120	could	only	inhibit	50%	of	binding	(Figure	2C),	consistent	with	Ba120	inability	to	reduce	holo-Tf	 internalization	 (Figures	 1D,	 2A).	 When	 measured	 on	 mouse	 TfR1	 using	 the	p815	mouse	cell	line,	H7-Fc	displayed	an	EC50	of	0.8	nM	(Figure	2D),	in	the	same	range	as	the	EC50	for	human	TfR1	measured	in	Raji	cells	(0.3	nM).	Finally,	analysis	of	antibody	(1	nM)	binding	 in	 the	presence	of	 increasing	 concentrations	of	holo-Tf	 at	4°C	 showed	that	 in	Raji	 cells,	H7-Fc	binding	 to	human	TfR1	could	be	 fully	 inhibited	(IC50	115	nM).	Conversely,	Ba120	binding	was	 inhibited	only	by	50%	even	 in	 the	presence	of	a	1000	molar	 excess	 of	 holo-Tf	 (Figure	 2E).	 Altogether,	 these	 results	 indicate	 a	 competitive	inhibition	of	holo-Tf	binding	by	H7	(i.e.,	the	H7	epitope	on	TfR1	overlaps	with	the	holo-Tf	 binding	 site).	 Molecular	 modeling	 confirmed	 the	 TfR1-H7	 (red)	 interaction,	 and	showed	that	the	Ba120	epitope	(green)	was	away	from	the	holo-Tf	binding	site	(Figure	
S3).		
Anti-TfR1	antibody	intrinsic	cytotoxic	activity		After	 confirming	 that	 the	 ERY-1	 and	 Raji	 cancer	 cell	 lines	 are	 sensitive	 to	 the	 iron	chelator	deferoxamine	(DFO)	(Figure	3A,	right	panel),	these	cell	lines	were	used	to	test	the	effect	of	the	H7	and	Ba120	antibodies	on	cell	growth.	After	5	days	of	incubation,	H7-Fc	and	H7-IgG1	strongly	decreased	the	viability	of	both	cell	lines	(IC50	in	the	range	of	0.1	µg/mL)	(Figure	3A).	Conversely,	Ba120	had	a	limited	effect,	in	agreement	with	its	lower	competition	with	holo-Tf	(Figures	2C,	2E).	Moreover,	H7-IgG1	reduced	rapidly	(4h)	the	levels	of	the	intracellular	labile	iron	pool	(LIP)	in	Raji	and	ERY-1	cells,	while	Ba120	had	a	more	 limited	 effect,	 especially	 at	 the	 lowest	 concentration	 used	 (1.5	 µg/mL)	 (Figure	
3B).	 In	ERY-1	cells,	apoptosis	could	be	detected	already	after	1	day	of	 incubation	with	
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H7-Fc	or	H7-IgG1.	After	3	days,	the	percentage	of	apoptotic	cells	was	higher	than	50%	using	 5nM	 of	 H7-Fc	 or	 H7-IgG1	 (corresponding	 to	 0.5	 µg/mL	 and	 0.75	 µg/mL,	respectively).	Conversely,	 apoptosis	was	more	 limited	with	Ba120,	 even	when	used	at	high	concentration	(500	nM	corresponding	to	75	µg/mL)	(Figure	3C).	Apoptosis	upon	H7	treatment	was	also	detected	in	Raji	cells,	with	the	same	kinetics	than	in	ERY-1	cells,	but	 to	 a	 lesser	 extent,	 consistent	 with	 this	 cell	 line	 displaying	 autophagic,	 but	 not	apoptotic	cell	death	features	upon	iron	deprivation.	Then,	to	compare	apoptosis	induced	by	 rituximab	 (anti-CD20	 antibody)	 and	 by	H7,	 the	Bp3	 and	 Im9	B-cell	 lymphoma	 cell	lines	 (sensitive	 and	 resistant	 to	 rituximab-induced	 apoptosis,	 respectively)	 were	incubated	 with	 H7	 or	 rituximab.	 H7	 strongly	 induced	 apoptosis	 in	 both	 cell	 lines,	(Figure	 3D).	 In	 Bp3	 cells	 (rituximab-sensitive),	 the	 apoptotic	 rate	 was	 higher	 upon	incubation	with	H7	than	with	rituximab	(RX),	although	H7	effect	was	delayed	compared	with	rituximab.	Ba120	induced	apoptosis	in	both	cell	lines,	but	was	less	efficient	than	H7	(Figure	3D).	H7	also	induced	an	early	moderate	free	iron	level	decrease	in	both	Bp3	and	Im9	cell	lines	(Figure	S4).	Altogether,	these	in	vitro	data	indicate	that	the	holo-Tf	uptake	blockade	by	H7	induces	apoptosis	in	leukemia	and	lymphoma	cell	lines,	including	those	resistant	to	rituximab,	likely	by	reducing	the	LIP.		
H7	fate	upon	TfR1	binding	Upon	binding	of	its	natural	ligand	holo-Tf	TfR1	is	rapidly	internalized	and	recycled	after	holo-Tf	has	released	iron	in	the	endosomes.	In	physiological	conditions,	TfR1	expression	depends	on	LIP	level	through	the	regulation	of	TfR1	mRNA	stability	(for	review,	see	Ref.	5).	 Previously	 described	 anti-TfR1	 competitive	 inhibitory	 antibodies	 decreased	 TfR1	levels	through	antibody-dependent	TfR1	routing	to	the	lysosome	where	it	 is	degraded.	Degradation	of	TfR1	upon	non-ligand	competitive	anti-TfR1	antibody	has	been	shown	to	
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be	enhanced	by	high	affinity	or	dimeric	receptor	binding	compared	to	lower	affinity	or	monomeric	 binding	 of	 TfR1.19,	 20	 Here,	 incubation	 of	 Raji	 cells	 with	 the	 high	 affinity	bivalent	anti-TfR1	H7	(5	µg/mL)	 for	36h	 led	 to	TfR1	 level	 increase.	Hypoxia-inducible	factor	1-alpha	(HIF-1α),	the	stability	of	which	is	affected	by	LIP	through	iron-dependent	proteases,21	 was	 also	 strongly	 increased	 by	 H7	 treatment	 (Figure	 3E).	 TfR1	 increase	upon	treatment	was	strongly	prevented	by	translation	inhibition	by	cycloheximide	and	slightly	 increased	 by	 NH4Cl	 treatment	 that	 limits	 lysosome	 acidification	 (Figure	 3F).	Conversely,	 holo-Tf	 and	 Ba120	 treatment	 reduced	 TfR1	 level	 after	 36h	 of	 treatment	(Figure	 3E).	 These	 data	 suggest	 that	 unlike	 Ba120,	 H7	 does	 not	 interfere	 with	 TfR1	recycling	 and	 induces	 limited	 TfR1	 degradation.	 Finally,	 H7	 binding	 to	 TfR1	 was	 not	decreased	 at	 pH	 6	 compared	 with	 pH	 7	 (Figure	 S5),	 indicating	 that,	 like	 apo-Tf,	 H7	might	 not	 be	 released	 in	 the	 endosome	 and	 could	 be	mostly	 recycled	 back	 to	 the	 cell	surface	together	with	TfR1.	However,	unlike	apo-Tf,	which	has	reduced	affinity	for	TfR1	at	extracellular	pH,22	H7	should	not	dissociate	at	the	cell	surface,	and,	therefore,	reduce	strongly	 the	accessibility	of	 the	 recycled	TfR1	 to	 iron-charged	holo-Tf,	 thus	explaining	H7	high	iron	deprivation	efficiency.		To	explore	the	potential	consequences	of	the	TfR1	modulation	by	H7	observed	 in	vitro	on	H7	PK/pharmacodynamics	(PD),	the	biodistribution	of	a	mixture	of	125I-labeled	H7-Fc	 and	 131I-labeled	 irrelevant	 scFv2-Fc	 antibodies	was	 evaluated	 in	mice.	The	 scFv2-Fc	format	 was	 chosen	 because,	 differently	 from	 the	 IgG1	 format,	 it	 can	 cross-react	 with	mouse	TfR1	(Figure	1C).	Nude	mice	bearing	subcutaneous		ERY-1	tumor	cell	xenografts	received	one	intravenous	(i.v.)	injection	of	the	two	antibody	mixture	(6	µg,	5	µCi/each)	(n=4).	The	percentage	of	 the	 injected	dose	 (%ID)	 after	48	h	 in	 each	 individual	mouse	was	 similar	 for	 H7-Fc	 and	 the	 irrelevant	 scFv2-Fc	 antibody,	 consistent	 with	 the	well-
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described	enhanced	permeability	and	retention	(EPR)	effect	in	tumors23	(Figure	4A,	left	
panel).	Individual	variations	among	animals	could	be	explained	by	the	different	tumor	sizes	 (300	 to	 800	mm3).	 However,	 as	 indicated	 by	 the	 organ	 repartition	 index,	 H7-Fc	specificity	for	mouse	TfR1	resulted	in	increased	radioactivity	associated	with	the	tumor	compared	with	the	irrelevant	scFv2-Fc	antibody	(ratio	>1)	(Figure	4A,	right	panel,	and	
Figure	S6).	In	a	parallel	experiment,	H7-Fc	(80	µg)	was	i.v.	injected	in	C57Bl/6	wild	type	(WT)	mice	or	in	C57Bl/6	FcRn	knock-out	(KO)	mice	and	titered	by	ELISA	in	the	serum	(Figure	4B).	As	seen	Figure	4B,	 in	WT	mice,	H7-Fc	was	cleared	from	the	serum	more	rapidly	 than	 the	 irrelevant	 scFv2-Fc,	 likely	due	 to	 its	binding	 to	mouse	TfR1.	AUC	and	serum	 clearance	 (CL)	 classic	 constants	 are	 reported	 in	 Table	 S1.	 A	 two-compartment	model	 (plasma	 and	 intracellular/central	 compartments)	was	 designed	 to	 describe	 the	cellular	 uptake	 and	 cellular	 recycling	 of	 the	 antibodies	 (see	 materials	 and	 methods	section	and	Figure	4C).	This	model	is	derived	from	previously	published	models.24,	25	In	our	model,	 the	 apparent	 distribution	 volume	 (VD)	 was	 higher	 for	 H7-Fc	 than	 for	 Irr-scFv2-Fc,	 both	 in	WT	 and	 C57Bl/6	 FcRnKO	mice,	 consistent	 with	 higher	 intracellular	localization	of	H7-Fc	(2.5	mL	versus	1	mL	for	H7-Fc	and	Irr-scFv2-Fc,	respectively,	(LRT,	p<0.0005)).	As	expected,26	the	recycling	of	 Irr-scFv2-Fc	(kCS)	was	decreased	in	FcRnKO	mice	 due	 to	 the	 lack	 of	 lysosomal	 rescue	 associated	 to	 the	 absence	 of	 FcRn15	 and	consistently,	 its	 elimination	 half-life	 T1/2	 was	 lower	 in	 FcRnKO	 compared	 to	 WT	background	(1.7	to	7.9	days,	LRT,	p<0.0005).	However,	strikingly,	if	the	recycling	of	H7-Fc	 was	 also	 decreased	 in	 FcRnKO	mice,	 its	 elimination	 half-life	 was	 not	 affected	 and	remained	 around	 4	 to	 5	 days	 in	 both	 genetic	 backgrounds	 (Figure	 4D	 and	 Table	 I).	Since	both	FcRn	and	antibody	factors	were	quantified	simultaneously	in	the	multivariate	model,	 the	 effects	 due	 to	 FcRn	 or	 TfR1	 binding	 and	 recycling	 are	 measured	independently.	Therefore,	 this	 could	 indicate	 that	H7-Fc	 is	protected	 from	elimination	
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by	its	binding	to	TfR1.	Altogether,	the	biodistribution	and	PK	results	reveals	a	dominant	target	mediated	stabilization	mechanism	for	H7-Fc.	Finally,	nude	mice	with	established	s.c.	ERY-1	 tumor	cell	xenografts	were	 treated	with	H7-Fc	 (5	mg/kg	 via	 intraperitoneal	 (i.p.)	 administration	 twice	 a	week)	 or	 phosphate-buffered	 saline	 (PBS)	 (n=5	 animals/group).	 After	 4	 weeks	 of	 treatment,	 two	 animals	were	cured	in	the	H7-Fc	group.	Moreover,	western	blot	analysis	of	the	tumors	(Figure	
4E)	 showed	 that	 TfR1	 levels	 were	 increased	 in	 the	 tumors	 of	 the	 other	 three	 mice	treated	with	 H7-Fc	 compared	with	 the	 tumors	 of	 the	 PBS	 group.	 IHC	 analysis	 of	 one	tumor	 for	 each	 group	 (900	 mm3)	 with	 an	 anti-TfR1	 antibody	 showed	 higher	 TfR1	staining	 in	 the	 H7-Fc	 treated	 sample	 (Figure	 4F).	 These	 data	 indicate	 that	 H7-Fc	treatment	upregulates	TfR1	in	vivo,	as	observed	in	vitro,	suggesting	that	tumors	treated	with	H7	undergo	iron	deprivation.		
The	H7	antibody	can	mediate	ADCC	Cytotoxic	effector	cells	require	interaction	with	the	Fc	portion	of	an	antibody	to	initiate	FcγR-dependent	 degranulation	 and	 perform	 ADCC.	 TfR1	 is	 a	 rapidly	 internalizing	receptor,	and	H7	was	isolated	on	the	basis	of	 its	rapid	internalization.27	 	To	determine	whether	this	feature	affected	H7-mediated	ADCC,	the	antibody	was	added	to	the	target	cells	(Raji	cells	or	HMC11	cells)	for	30	min,	to	allow	TfR1	internalization,	before	addition	of	freshly	prepared	peripheral	blood	mononuclear	cells	(PBMC)	for	3h.	In	this	assay,	H7-IgG1,	induced	ADCC	in	HMC11	cells	(TfR1pos,	CD117pos,	CD20neg)	and	Raji	cells	(TfR1pos,	CD117neg,	CD20pos),	with	comparable	efficiency	(Figure	5A),	while	the	anti-CD117	mAb	2D1	(human	IgG1),	and	the	anti-CD20	rituximab	(human	IgG1)	mediated	toxicity	only	on	HMC11	 and	 Raji	 cells,	 respectively.	 Compared	 with	 H7-IgG1,	 H7-Fc	 effect	 was	 more	
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limited	 and	 observable	 only	 after	 16h	 of	 incubation	 with	 PBMC	 (Figure	 5B).	 This	difference	was	confirmed	in	two	other	cell	lines	(Figure	S7).	
	
In	vivo	effects	of	H7	Nude	mice	with	established	s.c.	ERY-1	tumors	were	treated	with	PBS	(controls)	or	H7-Fc	(100	µg	per	 i.p.	 injection	twice	a	week)	for	4	weeks	(n=7/group).	Mice	were	sacrificed	when	tumors	reached	1600	mm3.	Compared	with	controls,	 tumor	growth	 in	the	H7-Fc	group	was	significantly	reduced	(p<0.05)	during	the	treatment	time.	Specifically,	 three	mice	responded	to	the	treatment,	and	one	was	totally	cured	(Figure	6	A-B).	However,	survival	was	not	 significantly	 improved	 (Figure	6C).	Weight	 loss	was	not	observed	 in	any	mouse	during	 the	experiment.	 In	 the	next	experiment,	 (Figure	6	D),	 in	which	H7-IgG1	(200	µg	per	i.p.	injection	twice	a	week)	was	used	instead	of	H7-Fc,	tumor	regression	was	observed	 in	all	mice	treated	with	H7-IgG1,	but	 in	none	of	 the	PBS	group	or	of	 the	irrelevant	IgG1	group	(n=6	mice/group).	In	five	mice	of	the	H7-IgG1	group,	tumors	were	undetectable	 at	 day	 60	 after	 the	 end	 of	 the	 treatment.	 Finally,	 treatment	with	 a	 non-glycosylated	 variant	 of	H7-IgG1	 (H7-IgG1	del297,	 defective	 in	ADCC	 and	ADCP	due	 to	reduced	 affinity	 for	 the	 Fcγ	 receptors	 and	 defective	 in	 complement-dependent	cytotoxicity,	 due	 to	 reduced	 affinity	 for	 C1q,28	 (n=6	 mice)	 inhibited	 tumor	 growth	(p<0.05)	 and	 two	 mice	 were	 cured.	 Therefore,	 H7	 treatment	 reduced	 ERY-1	 tumor	growth,	 with	 a	 stronger	 effect	 observed	 with	 the	 IgG1	 than	 the	 scFv2-Fc	 format.	Altogether,	 these	 results	 indicate	 that	 the	 higher	 therapeutic	 efficiency	 of	 H7-IgG1	compared	with	H7-Fc	correlates	with	its	higher	ADCC	activity	in	vitro.				
Discussion	
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	Starting	from	a	panel	of	anti-TfR1	scFv	antibodies	that	were	isolated	for	their	rapid	cell	internalization	 upon	 antigen	 binding,	 we	 engineered	 bivalent	 antibodies	 harboring	 a	human	 Fcγ1.	 We	 found	 that	 for	 the	 scFv2-Fcγ1	 format,	 H7-Fc	 was	 the	 most	 efficient	antibody	concerning	inhibition	of	holo-Tf	uptake	(Figure	1D).	This	was	due	to	H7	great	efficiency	 in	 blocking	 holo-Tf	 binding	 (2	 log	 lower	 molar	 concentrations	 of	 H7	 are	required	to	block	holo-Tf	binding,	and	2	log	higher	molar	concentrations	of	holo-Tf	are	required	to	block	H7	binding)	(Figure	2	C,	E).	H7-IgG1	maintained	this	feature,	but	lost	cross-reactivity	 to	 mouse	 TfR1	 (Figures	 1C,	 2D).	 This	 loss	 of	 cross-reactivity	 after	reformatting	 has	 previously	 been	 observed	 with	 other	 antibodies.29,	 30	 Despite	 the	similar	 apparent	 affinity	 of	 the	 two	 H7	 formats	 measured	 in	 Raji	 cells	 or	 by	 SPR	 on	recombinant	 human	 TfR1	 (Figure	 2B,	 S2),	 H7-IgG1-mediated	 ADCC	 in	 Raji	 cells	 was	strong,	 whereas	 H7-Fc	mediated	 limited	 ADCC	 (Figure	 5).	 This	 is	 surprising	 because	several	 studies	 reported	 that	 the	 Fc	 domain	 of	 scFv2-Fc	 antibodies	 can	 direct	 effector	cell	toxicity	to	antigen-expressing	target	cells.31,	32	However,	geometry	differences	in	the	scFv2-Fc	 and	 the	 IgG1	 formats	 that	 modify	 Fc	 region	 access	 to	 the	 FcyR	 of	 immune	effector	 cells	 and	 affect	 antibody-dependent	 cell-mediated	 killing	 have	 also	 been	recently	reported.33		As	the	two	formats	were	not	produced	using	the	same	cell	system,	this	 discrepancy	 could	 be	 also	 due	 to	 differences	 in	 glycosylation	 enzymes	 between	HEK-293	T	(production	of	H7-Fc)	and	Chinese	hamster	ovary	(CHO)	cells	(production	of	H7-IgG1).	Indeed,	in	HEK-293	T	cells,	the	increased	content	of	N-acetylneuraminic	acid	(sialic	acid)	of	N-glycostructures34	can	reduce	 the	affinity	 for	FcγRIIIa,	 the	receptor	on	natural	killer	cells.35,	36		
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Incubation	of	cells	with	H7-Fc	or	H7-IgG1	increased	TfR1	levels	(Figure	3E)	similarly	to	incubation	 with	 the	 50	 kD	 dimeric	 (scFv)2	 H7	 antibody	 (H7-scFv2).6	 	 Therefore,	 the	presence	of	an	Fc	region	did	not	change	the	receptor	modulation.	To	our	knowledge,	this	property	is	unique	because,	like	the	anti-TfR1	Ba120	mAb	tested	in	this	study,	18	other	previously	described	high	affinity	anti-TfR1	antibodies	in	the	IgG1	format	decrease	TfR1	level	 through	 traffic	 diversion	 and	 degradation	 within	 lysosomes.10,	 11	 TfR1	 normal	trafficking	is	not	extensively	diverted	to	lysosome	by	H7	binding	(Figure	3F).	Combined	with	 the	 efficient	 iron	 deprivation	 that	 promotes	 TfR1	 translation,	 this	 property	contributes	to	the	TfR1	level	 increase	observed	 in	vitro	and	 in	vivo	upon	H7	treatment	(Figures	3E,	4D).	H7-mediated	iron	deprivation	is	higher	than	with	Ba120	in	ERY-1	and	Raji	cells	lines	(Figure	3B).	We	also	find	that	Ba120	increases	rapidly	soluble	iron	levels	in	Bp3	and	Im9	cells	lines	(Figure	S4).	Because	Ba120	induces	TfR1	degradation,	visible	after	36h	in	Raji	cells	(Figure	3E),	the	increase	in	soluble	iron	level	mediated	by	Ba120	is	probably	only	transient.	As	H7	binds	with	similar	affinity	to	TfR1	at	extracellular	and	endosomal	pH	(Figure	S5B),	H7	may	be	 recycled	at	 the	cell	 surface	with	 the	 receptor	after	 it	 has	 induced	 its	 internalization,	 thus	 immediately	 preventing	 TfR1	 association	with	 extracellular	 holo-Tf.	 This	mechanism	 of	 action	 could	 contribute	 to	 the	 fast	 and	strong	effect	observed	upon	incubation	with	H7	in	vitro	(apoptosis	detected	after	36h	in	the	4	 cell	 lines	 tested	 (Figure	3	C-D)).	 The	 increased	efficiency	 (>2	 log)	 of	ERY-1	 cell	viability	 inhibition	by	 the	bivalent	H7-IgG1	(IC50	0.5	nM),	H7-Fc	(IC50	1.4	nM)	and	H7-scFv2	(IC50	2	nM)6	compared	with	the	monovalent	H7-scFv	(IC50	200	nM)6	suggests	that	these	bivalent	antibodies	can	bind	to	two	proximal	TfR1	receptors	on	cells	in	which	the	receptor	 is	present	at	high	density.	Accordingly,	 lower	toxicity	 is	expected	in	cells	 that	express	 low	 levels	 of	 TfR1,	 as	 previously	 suggested	 for	 the	 anti-TfR1	mAb	 A247	 	 and	demonstrated	for	the	anti-TfR1	JST-TFR09	antibody.8	In	agreement,	no	obvious	toxicity	
		 15	
was	observed	in	mice	treated	with	H7-Fc	(cross-reactive	with	mouse	TfR1)	for	1	month	compared	 with	 untreated	 mice	 (PBS),	 indicating	 that	 despite	 background	 TfR1	expression	 in	many	 tissues,	 iron	deprivation	due	 to	H7	should	have	 limited	 toxicity	 in	
vivo.	However,	since	non-competitive	effector	competent	anti-TfR1	antibodies	have	been	shown	to	transiently	elicit	acute	clinical	signs	and	to	clear	immature	blood	reticulocytes	in	mice,37	it	is	not	excluded	that	such	a	toxicity	may	occur	with	the	competitive	anti-TfR1	H7	of	this	study.	This	will	need	to	be	determined	using	an	effector	function	competent	variant	of	scFv2-Fc	H7	in	mice.	As	 TfR1	 is	 expressed	 at	 low	 level	 by	many	 cell	 types,	 we	 hypothesized	 that	 antigen-dependent	recycling	of	H7	could	protect	this	antibody	from	degradation	in	an	FcRn-like	process.	 Indeed,	 FcRn	 and	 TfR1	 share	 similar	 intracellular	 trafficking	 and	 both	 can	rescue	 their	 respective	 ligands	 from	 lysosomal	 degradation.15,	 38-40	 To	 test	 this	hypothesis,	 because	human	Fcγ1	binding	 to	mouse	FcRn	 receptors	 allows	 relevant	PK	observations	 in	 mice,41	 we	 compared	 the	 PK	 of	 the	 cross-reactive	 H7-Fc	 in	 WT	 and	FcRnKO	mice.	In	our	model,	compared	to	WT	mice,	the	elimination	half-life	of	H7-Fc	was	only	weakly	affected	in	FcRnKO	mice	(Figure	4D),	while	the	elimination	half-life	of	the	irrelevant	scFv2-Fc	antibody	was	dramatically	 reduced,	as	previously	 reported	 for	 this	antibody	format.32,	42	Moreover,	the	apparent	volume	of	distribution	of	H7-Fc	was	more	than	 twice	 larger	 compared	 to	 the	 apparent	 volume	 of	 distribution	 of	 the	 irrelevant	scFv2-Fc.	 Additionally,	 H7	 bound	 with	 similar	 affinity	 to	 TfR1	 at	 extracellular	 and	endosomal	pH.	 	These	observations	are	consistent	with	the	hypothesis	of	a	mechanism	of	 stabilization	 of	H7	 through	TfR1	 binding	 and	 recycling.	 This	 could	 also	 explain	 the	antitumor	 effect	 of	 H7	 in	 a	 scFv2	 format	 in	 nude	 mice	 harboring	 s.c.	 ERY-1	 tumors,	although	 no	 therapeutic	 effect	 was	 expected	 because	 of	 its	 small	 size	 (50	 kDa)	 and	potential	fast	serum	clearance	through	kidneys.43,	44	H7	specificity	and	its	unique	mode	
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of	interaction	with	TfR1	(it	acts	like	an	exact	mimic	of	the	natural	ligand)	could	increase	its	 persistence	 in	 vivo	 through	 an	 FcRn-like	mechanism	 that	 is	 independent	 of	 the	 Fc	part	of	the	antibody.			
In	vitro,	H7	had	a	strong	inhibitory	effect	in	different	lymphoma	and	leukemia	cell	lines,	including	 the	 rituximab-resistant	 B-cell	 lymphoma	 cell	 line	 Im9	 (Figure	 3	 A,D).	 H7	drastically	reduced	cell	viability	of	Raji	and	ERY-1	cells	(IC50	in	the	range	of	0.1	µg/mL)	and	 induced	 apoptosis	 in	 ERY-1,	 Raji,	 Bp3	 and	 Im9	 cells.	 In	 Raji	 cells,	 in	 addition	 to	limited	 apoptosis,	 autophagic	 cell	 death	 features	 were	 observed	 with	 increased	 cell	granularity	 and	 volume	 (not	 shown),	 as	 previously	 described	 with	 H7-scFv2.6	 Ba120	showed	a	delayed	and	weaker	effect	compared	with	H7.	In	vitro,	IC50	as	low	as	those	for	H7	 in	cancer	cells	have	been	observed	only	with	 the	recently	described	anti-TfR1	 JST-TFR09	antibody	in	adult	T-cell	leukemia/lymphoma	(ATLL)	cells.	8	Moreover,	in	Raji	and	ERY-1	 cells,	 H7	 also	 induced	 immunogenic	 cell	 death	 features45	 with	 exposure	 of	calreticulin	at	the	cell	surface	of	pre-apoptotic	cells	and	ATP	release	(data	not	shown).	Similar	effects	were	also	observed	upon	incubation	with	DFO	in	both	cell	lines	(data	not	shown).	Therefore,	in	addition	to	the	direct	effect	on	tumor	cells	and	on	the	recruitment	of	cytotoxic	cells,	H7-mediated	iron	deprivation	could	also	prime	the	adaptive	immune	response.	
	
In	vivo,	in	nude	mice	xenografted	with	ERY-1	erythroleukemia	cells,	H7-IgG1	treatment	allowed	curing	five	of	the	six	mice	with	established	tumors.	 Iron	deprivation	is	part	of	the	 mechanism	 of	 action	 of	 H7-IgG1	 because	 H7-Fc	 and	 H7-IgG1	 del297	 (both	 with	limited	 effector	 function)	 reduced	 tumor	 growth	 compared	 with	 PBS	 or	 irrelevant	antibody	 treatment.	 However,	 effector	 functions	 improve	 the	 effect	 of	 TfR1	 targeting	
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because	 H7-IgG1	 was	 clearly	 more	 efficient	 than	 H7-Fc	 and	 H7-IgG1	 del297.	 The	upregulation	of	TfR1	mediated	by	LIP	decrease	through	the	Iron	regulatory	protein/iron	responsive	 element	 (IRP/IRE)	 system,1	 likely	 potentiates	 antibody-mediated	 immune	effector	 recruitment	 to	 tumor	 cells	 in	 H7-IgG1-treated	 mice,	 and,	 therefore,	 iron	deprivation	may	both	participate	directly	and	indirectly	to	the	overall	drastic	efficiency	of	 H7-IgG1	 treatment.	 The	 lower	 H7-Fc	 efficacy	 could	 also	 be	 linked	 to	 a	 lower	localization	in	the	tumor	compared	with	H7-IgG1	because	of	antigen-driven	localization	of	the	cross-reactive	H7-Fc	in	other	tissues.	It	could	be	interesting	to	produce	an	effector	function-competent	H7-Fc	in	CHO	cells	and	test	its	effect	in	this	erythroleukemia	model,	or	 in	 syngeneic	 tumor	models	 to	 address	H7	 therapeutic	 effect	 and	 toxicity	 in	 a	more	relevant	setting.	In	 conclusion,	we	developed	 a	 promising	 fully	 human	 anti-TfR1	 antibody	with	unique	PK/PD	properties	that	displays	high	therapeutic	efficiency	in	an	erythroleukemia	mouse	model	with	no	apparent	toxicity.	As	TfR1	expression	is	 increased	in	many	tumors,	this	antibody	could	also	be	active	in	other	cancer	types.		
	
Material	and	methods	
	
Antibodies,	cells	and	reagents	The	scFv2-Fc	antibodies	were	produced	in	HEK-293	T	cells46	 	and		the	H7-IgG1	in	CHO	cells	 (EVITRIA,	 Switzerland).	 The	 anti-TfR1	 H7-IgG1	 del297	 and	 Ba120	 mAbs	 were	provided	by	A.	Fontayne	(LFB,	France).	The	Bp3,	Im9,47	Raji,	and	ERY-148		cell	lines	were	grown	 in	 RPMI;	 the	 P815	 and	 HMC11	 cell	 lines	 in	 IMDM	 (both	 media	 were	supplemented	with	10%	fetal	bovine	serum	and	antibiotics).	Commercial	antibodies	and	
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reagents	 for	 fluorescent-activated	 cell	 sorting	 (FACS),	 western	 blotting	 and	immunohistochemistry	(IHC)	are	listed	in	the	on-line	supplement.		
In	vitro	assays	Holo-Tf	 uptake,	 apparent	 affinity	 and	 ligand	 competition,	 cell	 viability	 and	 apoptosis	assays	were	performed	as	described.	Intracellular	free	iron	levels	were	measured	using	calcein,	as	described	 in	Ref.	49.	For	 the	ADCC	assay,	 target	cells	were	stained	with	 the	PKH26	fluorescent	dye.	Then,	50	μL	of	stained	cells	(50,000	cells)	were	combined	with	50	µL	of	antibody	for	30	minutes,	followed	by	50	μL	(2.5	106	cells)	of	PBMC	at	37°C	for	3h.	Cells	were	stained	with	7-AAD	before	FACS	analysis.	Details	are	given	in	the	on-line	supplement.	 Cells	 were	 incubated	 with	 50	 µg/mL	 cycloheximide	 and	 10	 mM	 NH4Cl	(SIGMA)	in	some	experiments.		
Pharmacokinetics	Ten	 WT	 C57Bl/6	 (Janvier,	 Saint-Berthevin,	 France)	 and	 FcRnKO	 (B6.Cg-Fcgrttm1Dcr)50	(Jackson	Laboratory,	Bar	Harbor,	ME)	mice	received	an	 i.v.	retro-orbital	injection	of	80	µg	 of	 scFv2-Fc	 (single	 dose).	 From	 2h	 to	 day	 21	 post-injection,	 blood	 samples	 were	collected	and	scFv2-Fc	 titered	by	ELISA	 (see	on-line	 supplement).	A	 two-compartment	model	 was	 designed	 to	 describe	 cellular	 uptake	 of	 antibodies.	 Compartments	 were	serum	(S)	and	intracellular	(C)	and	kSC,	kCS	and	kE	are	cellular	uptake,	cellular	recycling	and	 intracellular	 elimination	 rate	 constants,	 respectively	 (Figure	 4C).	 The	 PK	 of	antibodies	 was	 analyzed	 using	 population	 PK	 modelling	 using	 Monolix®2018	 suite	(Lixoft,	 Orsay,	 France).	 Interindividual	 and	 residual	 variabilities	 of	 the	PK	parameters	were	 estimated	 using	 exponential	 and	 proportional	 models,	 respectively.	 The	association	of	FcRn	(WT	vs.	KO)	and	antibody	(Irrelevant	scFv2-Fc	vs	H7-Fc)	factors	was	
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tested	as	dichotomous	covariates	on	PK	parameter	interindividual	distributions.	These	covariates	 were	 tested	 using	 likelihood	 ratio	 tests	 (LRT)	 based	 on	 objective	 function	value	(OFV).	From	pairs	of	nested	models	(i.e.,	models	with	vs.	without	covariate),	 the	difference	 between	 their	 OFV	 was	 tested	 using	 a	 chi-square	 test.	 A	 covariate	 was	considered	as	significant	if	corresponding	p-value	was	<	0.05.	
Biodistribution	A	mixture	 of	 125I-labeled	H7-Fc	 and	 131I-labeled	 irrelevant	 scFv2-Fc	 (6	 µg,	 5	 µCi	 each)	was	 injected	 (i.v.)	 in	 four	 6	 to	 8-week-old	 female	 athymic	 mice	 (Harlan	 Labs)	xenografted	with	ERY-1	cells	 (2	×	106)	by	s.c.	 injection	 in	 the	 flank	and	 in	 four	6	 to	8-week-old	 BALB/C	 mice	 (Envigo,	 France).	 After	 48h,	 mice	 were	 killed	 and	 the	radioactivity	of	both	iodine	isotopes	was	quantified	in	all	organs	and	tissues	by	using	a	dual-channel	γ	scintillation	counter.			
In	vivo	erythroleukemia	model	and	H7-based	therapy	When	tumors	reached	an	average	volume	of	100	mm3,	mice	bearing	s.c.	ERY-1	tumors	were	randomized	in	different	treatment	groups	(6	to	8	animals/group):	100	µg	of	H7-Fc,	200	µg	of	H7-IgG1,	H7-IgG1	del297	or	PBS,	all	by	i.p.	injection	twice	a	week	for	4	weeks.	For	 survival	 analysis,	 mice	 were	 sacrificed	 when	 tumors	 reached	 a	 volume	 of	 1,600	mm3.	Mice	were	considered	as	cured	when	tumor	was	non	more	palpable.	The	statistical	analyses	are	described	in	the	on-line	supplement.		
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Legends	to	the	figures		
Figure	1:	Preliminary	characterization	of	the	reformatted	anti-TfR1	scFvs	
(A)	 Graphic	 representation	 of	 the	 scFv2-Fc	 and	 the	 IgG1	 formats,	 in	 grey	 variable	domains	 (light	 grey,	 VH;	 dark	 grey,	 VL),	 in	 black,	 constant	 domains.	 (B)	 Validation	 of	TfR1	surface	expression	on	the	lymphoma	Raji	cell	line	(human)	and	P815	mastocytoma	cells	 (mouse)	by	FACS	 (FC500	 cytometer)	with	 a	 commercial	mouse	anti-human	TfR1	IgG	or	a	rat	anti-mouse	TfR1	IgG	(10	µg/mL)	followed	by	anti-mouse	IgG	or	anti-rat	IgG	fluorescent	secondary	antibodies,	respectively,	or	with	fluorescent	holo-Tf	(500	nM)	(C)	Detection	of	 the	binding	of	 the	panel	of	anti-TfR1	antibodies	reformatted	 into	bivalent	scFv	by	fusion	to	Fc	(upper	panel)	or	in	full-length	human	IgG1	(lower	panel)	to	the	Raji	or	the	mouse	P815	cell	lines,	as	indicated.	Binding	is	detected	with	an	anti-human	IgG1	antibody	 conjugated	 to	 FITC	 and	 FACS	 analysis	 (FC500	 cytometer).	 Dark	 grey	 peaks	represent	 fluorescent	 background	 of	 the	 secondary	 antibody	 alone	 or,	 in	 case	 of	 the	detection	of	fluorescent	holo-Tf	binding,	cell	autofluorescence.	(D)	scFv2-Fc	(left	panel)	and	full	length	IgG1	(right	panel)	interference	with	fluorescent	holo-Tf	internalization	in	Raji	 cells:	 antibodies	 at	 the	 indicated	 concentrations	 are	 combined	 with	 fluorescent	holo-Tf	(500	nM)	and	incubated	at	37°C	with	Raji	cells	 for	3	h	then	cells	are	collected,	washed	 with	 PBS	 and	 analyzed	 by	 FACS.	 Results	 are	 expressed	 in	 Mean	 Fluorescent	Intensity	 (MFI)	 relative	 to	 cells	 incubated	with	 fluorescent	holo-Tf	only.	 Irr,	 irrelevant	antibody	 of	 the	 same	 format.	 The	 data	 shown	 are	 representative	 of	 3	 independent	experiments.		
		 25	
Figure	 2:	 Characterization	 of	 the	 anti-TfR1	 H7	 scFv2-Fc	 and	 full	 length	 IgG1	
antibodies	
	(A)	 Interference	 of	 H7-Fc	 and	H7-IgG1	 (5	 µg/mL)	 (left	 and	 right	 panel,	 respectively)	with	the	internalization	of	10	µM	or	1	µM	Alexa	488-conjugated	holo-Tf,	measured	as	in	
Figure	1.	(B)	Apparent	affinity	of	H7-Fc,	H7-IgG1	and	Ba120	(mouse	monoclonal	anti-TfR1	IgG1)	and	of	Alexa	488-conjugated	holo-Tf	for	human	TfR1	measured	by	detection	of	 the	 binding	 of	 increasing	 concentrations	 of	 antibody/holo-Tf	 in	 Raji	 cells	 at	 4°C.	Bound	antibodies	were	detected	with	a	mouse	anti-human-Fc	fluorescent	antibody	and	analyzed	by	 FACS	 (Gallios	 cytometer);	 results	 are	 expressed	 as	MFI	 in	 function	of	 the	primary	antibody	concentration.	The	EC50	values	(nM)	are	indicated.	(C)	Measurement	of	the	fluorescence	signal	in	Raji	cells	after	incubation	(at	4°C	for	1h)	with	500	nM	Alexa	488-conjugated	 holo-Tf	 and	 increasing	 concentrations	 of	 H7-Fc,	 H7-IgG1,	 irrelevant	scFv2-Fc	antibody,	or	Ba120.	Results	 are	expressed	as	 the	%	MFI	 compared	with	 cells	incubated	 with	 holo-Tf	 alone.	 (D)	 Apparent	 affinity	 of	 H7-Fc	 and	 H7-IgG1	 for	 mouse	TfR1	measured	by	detection	of	 the	binding	of	 increasing	concentrations	of	antibody	 in	P815	cells	at	4°C	as	in	B,	(E)	H7-Fc	(left	panel)	and	Ba120	(right	panel)	binding	to	TfR1	in	Raji	 cells	 in	 the	presence	of	 increasing	 concentrations	 of	 holo-Tf.	 Bound	 antibodies	were	 detected	 by	 FACS	 with	 anti-human-Fc	 or	 anti-mouse-Fc	 fluorescent	 secondary	antibodies,	 (Gallios	cytometer)	and	results	expressed	as	MFI.	The	 IC50	values	(nM)	are	indicated.	 In	B,	D	and	E,	 similar	EC50	 and	 IC50	determinations	were	obtained	 in	2	 to	3	independent	experiments	in	the	same	setting.	
		
Figure	3:	Functional	properties	of	 the	anti-TfR1	H7	scFv2-Fc	and	 full	 length	 IgG1	
antibodies	
		 26	
(A)	Viability	of	ERY-1	erythroleukemia	(upper	panel)	and	Raji	B-cell	lymphoma	(lower	panel)	 cells	was	assessed	with	 the	MTS	assay	after	 incubation	with	H7-Fc,	H7-IgG1	or	Ba120	(5	days).	Results	are	expressed	as	the	percentage	of	viable	cells	compared	with	untreated	cells.	The	 iron	chelator	DFO	was	also	tested	 in	the	same	conditions;	 the	IC50	values	 (µg/mL	 for	 antibodies	 or	 µM	 for	 DFO)	 are	 indicated.	 The	 irrelevant	 scFv2-Fc	antibody	(Irr-Fc)	did	not	have	any	effect	on	cell	viability	(H7-Fc	panel).	(B)	Variation	of	intracellular	soluble	iron	levels	in	ERY-1	and	Raji	cells	induced	by	incubation	with	DFO,	H7-IgG1	or	Ba120	at	37°C	for	4h	and	8h.	 	Before	addition	of	the	antibodies,	cells	were	labeled	with	 the	 intracellular	 iron-chelating	dye	calcein.	Calcein	 fluorescence,	which	 is	quenched	when	chelated	to	 iron,	was	measured	by	FACS.	Results	are	expressed	as	 the	percentage	 of	 change	 in	 the	 fluorescence	 signal	 relative	 to	 untreated	 cells	 (NT).	Apoptosis	induction	in	(C)	ERY-1	and	Raji	cells	and	in	(D)	Bp3	and	Im9	B-cell	lymphoma	cells	after	incubation	with	H7-Fc,	H7-IgG1	(or	an	irrelevant	antibody	in	the	same	format,	Irr.),	 Ba120,	 or	 rituximab	 (RX,	 human	 IgG1;	 only	 in	 D)	 for	 the	 indicated	 time.	 After	treatment,	cells	were	collected	and	stained	with	Annexin	conjugated	to	FITC	and	7-AAD,	and	analyzed	by	FACS.	Results	are	expressed	as	the	percentage	of	Annexin+/7AAD-	cells	(i.e.,	early	apoptotic	cells)	compared	with	untreated	cells.	(E)	Comparative	effect	of	TfR1	H7-IgG1	(5	µg/mL)	and	holo-Tf	(10	µM)	treatment	(36	h)	of	Raji	cells	on	TfR1	and	HIF-1α	 levels.	Cells	were	alternatively	 treated	with	Ba120	or	 the	 corresponding	 irrelevant	antibody	 format	 at	 the	 same	 concentration.	 After	 treatment,	 protein	 extracts	 (20	 µg)	separated	by	SDS-PAGE	 (7%	polyacrylamide	 separation	gel)	 and	analyzed	by	Western	Blot.	 Quantification	 relative	 to	 actin	 is	 represented	 under	 the	Western	 Blot.	 The	 data	shown	are	representative	of	3	independent	experiments.	Irr,	irrelevant.	In	(F),	Raji	cells	were	 treated	 as	 in	 E.	 for	 18	 hr	 in	 the	 presence	 of	 10	 mM	 NH4Cl	 or	 50	 µg/mL	cycloheximide	(CHX)	as	indicated	or	not,	and	TfR1	levels	were	quantifyed	like	in	E.	
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Figure	4:	PK/PD	of	the	crossreactive	anti-TfR1	H7	scFv2-Fc	format	(H7-Fc)	
(A)	 Four	 nude	 mice	 bearing	 ERY-1	 tumors	 were	 injected	 i.v.	 with	 a	 mixture	 of	 125I-labelled	H7-Fc	and	131I	irrelevant	scFv2-Fc	(6	µg,	5	µCi	each).	After	48	h,	mice	were	killed	and	 the	 radioactivity	 in	 all	 organs	 and	 tissues	 was	 quantified	 by	 dual-channel	 γ	scintillation	 counting	 of	 both	 iodine	 isotopes.	 Results	 are	 expressed	 as	 the	 %	 of	 the	injected	dose	(ID)	in	the	whole	mice	(left	panels)	or	as	the	organ	specificity	index	at	the	time	of	 sacrifice	 (125I	%	cpm	relative	 to	 total	body	dose)/(131I	%	cpm	relative	 to	 total	body	dose	for	a	specific	organ)	(right	panels;	raw	data	are	available	in	Fig.	S6.)	(B)	Two	groups	of	 10	WT	and	FcRnKO	C57Bl/6	mice	were	 injected	 i.v.	with	4	mg/kg	of	H7-Fc	(about	80	µg)	(left	panel)	or	irrelevant	scFv2-Fc	(right	panel).	Antibody	concentration	in	serum	at	 various	 time	 after	 injection	was	 evaluated	by	ELISA	by	 Fc	 domain	detection	and	 normalized	 for	 each	mice	 to	 the	 concentration	measured	 2	 h.	 after	 injection.	 (C)	Two-compartment	 model	 describing	 antibody	 PK,	 where	 kSC,	 kCS	 and	 kE	 are	 cellular	uptake,	cellular	recycling	and	intracellular	elimination	rate	constants,	respectively	(see	methods	for	details).	(D)	Apparent	volume	of	distribution	(VD),	serum	elimination	half-life	 (T1/2)	and	recycling	constant	kCS	and	determined	by	 the	model,	 ***,	p<0,005	 (E,	F)	Groups	of	5	nude	mice	with	ERY-1	subcutaneous	tumors	of	200	mm3	were	treated	for	4	weeks	with	either	PBS	or	H7-Fc	(5	mg/kg	injected	i.p.	2	times	a	week)	and	(E)	all	tumors	were	 then	 processed	 for	 protein	 extraction	 and	Western	 Blot	 for	 TfR1	 detection,	 the	relative	 intensity	 of	 the	 TfR1	 band	 and	 the	 size	 of	 individual	 tumors	 at	 the	 time	 of	analysis	are	indicated.	(F)	One	tumor	of	similar	size	at	the	time	of	sacrifice	in	each	group	(900	mm3)	was	analyzed	by	IHC	for	TfR1	expression.		
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Figure	5:	ADCC	on	Raji	cells	using	 the	anti-TfR1	H7	scFv2-Fc	and	 full	 length	 IgG1	
antibodies		Live	lymphoma	Raji	cells	(A,	B)	or	mastocytoma	leukemic	HMC11	cells	(A)	were	stained	with	the	fluorescent	dye	PKH-67	and	then	pre-incubated	with	H7-IgG1	(A,B),	H7-Fc	(B),	anti-CD117	(2D1)	or	anti-CD20	(RX)	human	IgG1	at	the	indicated	concentrations	for	30	min	 before	 addition	 of	 freshly	 prepared	 PBMC	 (effector	 cells/target	 cells	 ratio	 =	 50).	After	3h	(or	16h),	cells	were	collected	and	stained	with	the	7-AAD	fluorescent	dye.	The	percentage	 of	 dead	 cells	 (7AAD+)	 among	 the	 target	 PKH-67+	 cells	was	 determined	 by	FACS	analysis.	In	A,	experiments	were	in	duplicate.		
Figure	 6:	 Therapeutic	 effect	 of	 the	 anti-TfR1	 H7	 scFv2-Fc	 and	 full	 length	 IgG1	
antibodies	ERY-1	cells	were	implanted	s.c.	into	nude	mice.	When	tumors	reached	200	mm3,	(A,	B,	C)	H7-Fc	(100µg	in	200	µL	of	PBS)	or	PBS	(200	µL)	or	(D,	E,	F)	H7-IgG1,	unglycosylated	H7-IgG1	(H7-IgG1	del297)	or	irrelevant	IgG1	(200µg	in	200	µL	PBS),	or	PBS	(200	µL),	were	injected	 i.p	twice	a	week	for	4	weeks	and	tumor	growth	was	monitored.	(A,	D)	Tumor	volume	of	 individual	mice	or	(B,	E)	average	tumor	volumes	and	(C,	F)	percent	of	mice	with	 tumor	 volume<1600	 mm3	 are	 represented	 as	 a	 function	 of	 time.	 Shaded	 zone	represent	 treatment	 period.	 Experiments	 A,B,C	 and	 D,E,F	 were	 performed	independently.	*,	p<0.05,	**,	p<0.01	
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Supplementary	material	
	 	
Material	and	methods	
scFv2-Fc	and	full	length	IgG1	antibody	design	and	production		To	obtain	scFv	 fused	with	 the	Fc	 fragment	of	human	 IgG1,	 the	cDNA	encoding	 the	six	anti-TfR1	scFv	antibodies1	or	anti-botulinum	toxin		(negative	control)1	were	NcoI/NotI-digested	from	the	phagemid	pHEN2	and	subcloned	into	the	pFUSE-hFc2(IL2ss)	vector3,	a	gift	 from	 Frank	 Perez,	 CNRS-Institut	 Curie,	 Paris,	 France.	 Soluble	 100	 kD	 scFv2-Fc	antibodies	were	produced	after	 transient	 transfection	of	HEK-293	T	cells	and	purified	using	protein	A	affinity	chromatography,	as	previously	described	in	Ref.4.	Full	length	H7-IgG1	 (CK	 isotype	 for	 the	 light	 chain)	 and	 2D1-IgG1	 (anti-CD117	 antibody)4	 were	produced	 in	 CHO	 cells	 from	 their	 VH	 and	 VL	 sequences	 by	 EVITRIA	 (EVITRIA,	Switzerland).	 C32-IgG1,	 F2-IgG1,	H9-IgG1,	 G9-IgG1,	H7-IgG1	del297	 (that	 has	 reduced	affinity	for	Fcγ	receptors	and	C1q	due	to	deletion	of	the	Asn297	residue)5	and	the	anti-TfR1	 mouse	 mAb	 Ba1206	 were	 a	 gift	 from	 Alexandre	 Fontayne	 (LFB,	 France).	 The	apparent	affinities	for	TfR1	of	the	two	H7-IgG1	and	H7-IgG1	del297	were	identical	(not	shown).	 Rituximab	 was	 from	 Roche.	 The	 irrelevant	 IgG1	 antibody	 was	 a	 human	polyclonal	 IgG	 (SIGMA,	 I2511).	 Antibody	 concentrations	 were	 verified	 by	 measuring	their	 A280nm	 by	 spectrophotometry	 (1	 UA	 at	 280	 nm	 corresponds	 to	 0.8	mg/mL)	 and	purity	was	checked	by	SDS-PAGE.	
	
Cell	lines	The	B-cell	 lymphoma	Bp3,	 Im97	 (a	 gift	 from	Nathalie	Bonnefoy,	 IRCM)	 and	Raji	B-cell	lymphoma	 cell	 lines,	 the	 erythroleukemia	 ERY-1	 cell	 line	 (a	 gift	 from	 Michel	 Arock,	LBPA,	 ENS	 Cachan,	 France),8	 and	 the	 BxPC3	 and	 CFPAC	 pancreatic	 cancer	 cell	 lines	
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(obtained	 from	 ATCC)	 were	 grown	 in	 RPMI-Glutamax	 supplemented	 with	 10%	 fetal	bovine	 serum	 (FBS;	 ThermoScientific	 SV30160.03)	 and	 with	 penicillin/streptomycin	(Gibco	 15240-062).	 The	 mouse	 P815	 (a	 gift	 from	 Nicolas	 Fazilleau,	 Institut	 Pasteur,	Paris,	France)	and	human	HMC11	mastocytoma	(a	gift	from	Michel	Arock,	ENS	Cachan,	France)	cell	lines	were	grown	in	IMDM.	Adherent	human	embryonic	kidney	HEK-293	T	cells	(a	gift	from	Laurent	Le	Cam,	IRCM)	were	grown	in	DMEM,	10%	FBS	and	antibiotics.	All	 cell	 lines	 were	 cultured	 at	 37°C	 in	 a	 humidified	 atmosphere	 with	 5%	 CO2	 and	screened	monthly	for	mycoplasma	infection.	
Commercial	antibodies	and	reagents	for	FACS,	western	blotting	and	IHC	Anti-human	CD71	 (Invitrogen,	 136800),	 -HIF1-α	 (Santa	 Cruz	Biotechnology,	 sc-8711),	and	 -beta-actin	 (Cell	 Signaling	 Technology	 3700S)	 antibodies	 were	 used	 for	 western	blotting.	 PE-conjugated	 anti-mouse	 TfR1	 (BD	 Pharmingen,	 553267),	 APC-conjugated	anti-human	 TfR1	 (BD	 Pharmingen	 551374),	 FITC-conjugated	 goat	 anti-human	 Fc	(SIGMA,	 F9512)	 or	 anti-mouse	 Fc	 (Invitrogen,	 31569)	 antibodies	were	 used	 for	 FACS	analysis	of	TfR1	levels.	Anti-human	TfR1	(SIGMA,	HPA028598)	was	used	for	IHC.	Human	holo-Tf	 was	 from	 SIGMA	 (T0665),	 DFO	 from	 Santa	 Cruz	 (Sc-203331;	 stock	 solution:	50mM	in	H20,	stored	at	4°C),	holo-Tf	conjugated	to	Alexa	Fluor	488	(holo-Tf-A488)	from	Invitrogen	 (T13342;	 50	 µM	 solution	 in	 PBS	 stored	 at	 4°C),	 and	 calcein-AM	 from	Invitrogen	(C3100MP;	stock	solution:	50	µM	in	DMSO	at	-20°C).	
	
Holo-Tf	uptake	measurement	Raji	cells	 (5×105)	were	washed	and	resuspended	 in	RPMI	medium	supplemented	with	1%	fetal	calf	serum	(FCS)	and	500	nM	holo-Tf-A488	together	or	not	with	antibodies	or	non-conjugated	holo-Tf	at	37°C	 for	3h.	Cells	were	 then	washed	with	 cold	PBS	and	 the	
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cell	 fluorescence	 associated	 with	 holo-Tf-A488	 uptake	 measured	 by	 FACS	 (FC500	 or	Gallios	 cytometer,	 Beckman	 Coulter).	 Preliminary	 experiments	 with	 an	 additional	incubation	 of	 cells	 with	 50mM	 glycine	 pH	 2.8/500mM	NaCl	 buffer	 for	 10	min	 at	 4°C	before	 FACS	 analysis	 showed	 that	 the	 fluorescence	 measured	 was	 more	 than	 95%	intracellular.	Therefore,	this	step	was	omitted	in	further	experiments	to	limit	the	steps	before	analysis	(Figure	S1B).	The	cell	mean	fluorescence	intensity	(MFI)	was	calculated	using	the	Flow	Jo	Version	10.1r7	software.		
Antibody	apparent	affinity	and	antibody/ligand	competition	All	incubation	steps	were	done	on	ice.	Raji	or	P815	cells	(5×105	cells)	were	resuspended	in	 100	 μL	 of	 FACS	 buffer	 [PBS,	 1%	 FBS]	 containing	 various	 concentrations	 of	 the	primary	antibody	 for	1h,	washed	twice	with	FACS	buffer,	and	 then	 incubated	with	 the	suitable	fluorescent	secondary	antibody.	After	a	final	wash,	cells	were	analyzed	by	FACS.	The	 apparent	 affinity	 was	 determined	 using	 the	 GraphPad	 software.	 For	 competition	experiments,	 cells	 were	 incubated	 with	 1nM	 antibody	 mixed	 with	 increasing	concentrations	 of	 holo-Tf	 (0.5pM	 to	 5µM).	 Then,	 bound	 antibodies	 were	 detected	 as	before.	 Alternatively,	 cells	 were	 incubated	 with	 500	 nM	 holo-Tf-A488	 mixed	 with	increasing	concentrations	of	antibody	(5nM	to	500	nM),	or	with	holo-Tf	(0.1	nM	to	10	µM).			
Biacore	analysis	SPR	 analyses	 were	 performed	 on	 a	 BIA3000	 apparatus	 at	 25°C	 in	 HBS-P	 (GE	Healthcare).	 For	affinity	measurements,	 anti-human	 IgG(Fc)	 (Human-antibody	 capture	Kit	(GE-Healthcare,		BR-1008-39)	was	covalently	immobilized	on	CM5	sensor	chip	using	EDC/NHS	 activation	 according	 to	 the	 manufacturer’s	 instructions	 (GE	 Healthcare).	
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Recombinant	homodimeric	human	TfR1	(produced	in	baculovirus/insect	cell	expression	system	 from	 pACGP67A-human	 TfR1	 vector	 (clone	 12130,	 Addgene))9	 at	 various	concentrations	was	injected	on	H7-IgG1	or	H7-Fc	captured	on	immobilized	anti-human-Fc	IgG	during	180s.	After	400s	of	dissociation	with	running	buffer,	the	sensor	chip	was	regenerated	using	MgCl2	3M.	The	KD	values,	 taking	 into	account	of	affinity	and	avidity	with	this	protocol,	were	calculated	using	a	steady-state	fitting	model	(BiaEvaluation3.2,	GE	 Healthcare).	 	 For	 competition	 analysis,	 human	 TfR1	 was	 injected	 at	 20nM	 during	180s	at	50µl/min	on	H7–IgG1	or	H7-Fc	captured	at	a	level	around	1800	RU.	During	the	dissociation	step	(very	slow	dissociation	rate),	human	holo-Tf	was	injected	at	different	concentrations	(1.25-1250nM)	to	displace	human	TfR1.		
Cell	viability	assay	Cells	(5	×	103)	were	plated	in	sixplicates	in	96-well	U-bottom	plates.	Antibody	solutions	diluted	 in	 culture	 medium	 were	 added	 to	 each	 well	 (total	 volume	 200	 µL).	 A	 well	containing	only	200	µL	of	 culture	medium	was	also	prepared	(reference).	After	4	 to	5	days,	cell	viability	was	estimated	using	the	CellTiter	96	AQueous	cell	proliferation	MTS	assay	(Promega,	G5430).	Briefly,	20	µL	of	MTS	reagent	was	added	to	each	well	and	left	for	 about	2	hours.	Plates	were	 then	 centrifuged	and	100	µL	of	 supernatant	 from	each	well	was	transferred	to	a	well	of	a	96-well	plate	(flat	bottom)	for	OD	reading	at	490	nm	using	a	microplate	reader	(Multiskan).			
Apoptosis	assay	ERY-1	cells	or	Raji	cells	or	the	B-cell	 lymphoma	Im9	and	Bp3	cells	(2.5	105	cells	or	1.5	105	cells	according	to	the	incubation	time)	were	plated	in	6-wells	plates	in	2ml	medium	and	 incubated	 with	 various	 concentrations	 of	 antibodies	 for	 24h	 to	 72h.	 Cells	 were	
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collected,	stained	using	the	Beckman	Coulter	IM3614	Apoptosis	Kit,	as	recommended	by	the	manufacturer,	 and	 analyzed	by	 FACS.	 Granularity	 over	 size	was	plotted	 and	 small	debris	 excluded	 for	 the	 relative	 quantification	 (%)	 of	 Annexin-positive	 and	 7-AAD-negative	cells	that	represent	early	apoptotic	cells.		
Intracellular	free	iron	detection		Intracellular	 free	 iron	 levels	 were	 measured	 using	 the	 fluorescent	 probe	 calcein,	 as	previously	described	Ref.10.	This	probe	binds	 to	 iron	 stoichiometrically	 in	a	 reversible	manner,	 forming	 fluorescence-quenched	calcein-iron	complexes.	Therefore,	higher	 cell	fluorescence	means	that	the	levels	of	 intracellular	 labile	 iron	pool	are	reduced.	Briefly,	cells	were	washed	and	resuspended	 in	medium	without	FCS	and	stained	with	250	nM	calcein-AM	 at	 37°C	 for	 5min.	 They	 were	 washed	 with	 complete	 medium	 and	resuspended	 in	 pre-warmed	 culture	 medium	 with	 1%	 FCS	 and	 incubated	 with	 the	studied	 antibodies	 or	 deferoxamine	 (DFO)	 for	 4	 or	 8h.	 Cell	 fluorescence	 due	 to	 free	calcein	 was	 measured	 by	 flow	 cytometry	 and	 the	 percentage	 increase	 in	 calcein	fluorescence	relative	to	untreated	control	was	calculated.		
Western	blotting	Raji	cells	(5.105	cells	in	2	mL)	were	treated	as	indicated	in	the	figure	legends	for	18	h	or	36	 h.	 Cells	 were	 harvested,	 centrifuged	 and	 washed	 with	 cold	 PBS.	 Proteins	 were	extracted	with	100	µL	of	boiling	lysis	buffer	(1%	SDS,	1	mM	sodium	orthovanadate,	10	mM	Tris	pH	7.4)/cell	pellet.	The	viscous	mix	was	sonicated	on	ice	four	times	at	25mA	for	5s,	 and	 then	 centrifuged.	 Protein	 concentration	was	 determined	 using	 the	 BCA	 assay	(Interchim).	Proteins	were	extracted	from	tumor	samples	using	a	lysis	buffer	containing	1%	Triton-X100,	0.5%	NP40,	1	mM	EDTA,	150	mM	NaCl,	10	mM	Tris-Hcl	pH	7.5,	100	
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mM	 NaF,	 1	 mM	 sodium	 orthovanadate,	 2	 mM	 phenylmethylsulfonyl	 fluoride	complemented	 with	 1	 tablet	 of	 protease	 inhibitors	 mixture	 for	 10	 mL	 (Roche	Diagnostics).	A	piece	of	tumor	of	10	mm3	was	cut	into	small	pieces,	and	then	0.5	mL	of	lysis	buffer	was	added	at	4°C	for	30min,	followed	by	grinding	with	glass	beads	using	a	Retsch	 MM300	 TissueLyser	 (Qiagen)	 at	 maximum	 power	 for	 3	 min,	 followed	 by	incubation	at	4°C	 for	30	min.	Protein	extracts	were	centrifuged	(12,000g	at	4°C	 for	30	min),	 and	proteins	 in	 the	 soluble	 fraction	 quantified	with	 the	BCA	 assay.	 For	western	blotting,	 20	 µg	 of	 protein	 were	 separated	 by	 SDS-PAGE	 on	 7%	 polyacrylamide	separation	 gels	 and	 transferred	 to	 PVDF	membranes.	 Membranes	 were	 blocked	 with	PBS/0.1%	Tween-5%	milk	at	room	temperature	(RT)	for	2h.	Incubations	with	primary	and	 secondary	 antibodies	 were	 done	 overnight	 at	 4°C	 and	 1h	 at	 RT,	 respectively.	Membranes	 were	 revealed	 with	 Western	 Lightning	 PLUS-ECL	 (Perkin	 Elmer)	 and	analyzed	with	a	G-box	(Syngene).	Quantification	was	done	using	the	ImageJ	software.		
ADCC	Raji	or	HMC11	cells	were	stained	with	the	PKH26	Red	Fluorescent	Cell	Linker	Mini	Kit	(SIGMA,	 Mini26-1	 KT)	 following	 the	 manufacturer’s	 instructions.	 Briefly,	 cells	 were	harvested	 and	 stained	with	PKH26	 fluorescent	 dye	 at	RT	 for	 3	min,	washed	 and	 then	cultured	 in	 complete	medium	overnight.	 Stained	 cells	 (50,000	 cells;	 50	μL/well)	were	then	 transferred	 in	 96-well	 U-bottom	 plates	 and	 combined	 with	 50	 µL	 of	 rituximab	(anti-CD20),	 2D1	 (anti-CD117),	 H7-IgG1	 or	 H7-Fc	 (0.2	 or	 1	 µg/mL	 final)	 at	 37°C	 for	30min.	Peripheral	Blood	Mononuclear	cells	(PBMC)	(50	μL,	2.5	106	cells)	isolated	from	normal	human	blood	using	Ficoll	were	added	to	the	mixture	(effector	to	target	cell	ratio	of	50).	After	3h	of	incubation	at	37°C,	cells	were	collected	and	stained	with	7-AAD	(0.1	
A	recycling	anti-TfR1	mAb	for	erythroleukemia	treatment,	Neiveyans	et	al.		
	 7	
µg/mL	 final)	 at	 4°C	 for	 15min	 before	 FACS	 analysis.	 The	 percentage	 of	 7-AAD+	 cells	among	the	PKH26+	cells	represented	the	target	cells	killed	by	PBMC.		
Determination	of	scFv2-Fc	concentration	in	serum	samples	by	ELISA	Blood	samples	were	centrifuged	at	1500g	for	15	min,	and	serum	samples	were	stored	at	-20°C	 until	 dilution	 (1000	 times	 in	 PBS)	 and	 scFv2-Fc	 titration	 by	 ELISA.	 An	 ELISA	sandwich	assay	(linear	range	from	10	to	150	ng	/mL)	was	specifically	developed	using	a	goat	 anti-human	 Fc	 as	 the	 capture	 antibody	 (Sigma,	 I-2126,	 10	 µg/mL)	 and	 a	 HRP-conjugated	goat	anti-human-Fc	antibody	as	the	detection	antibody	(A0170,	dilution	20	000).	 Samples	 were	 tested	 in	 duplicate	 and	 tittered	 in	 two	 independent	 ELISA	experiments.		
In	vivo	experiments	All	in	vivo	experiments	were	performed	in	compliance	with	the	French	regulations	and	ethical	 guidelines	 for	 experimental	 animal	 studies	 in	 an	 accredited	 establishment.	 In	some	 experiments,	 tumors	were	 isolated	 and	 prepared	 for	 IHC	 analysis	with	 an	 anti-TfR1	 antibody	 (IRCM	 Histology	 core	 facility)	 or	 for	 protein	 extraction	 for	 western	blotting.			
Statistical	analysis	(in	vivo	study	for	therapeutic	efficiency)	A	linear	mixed	regression	model	was	used	to	determine	the	relationship	between	tumor	growth	 and	 the	 number	 of	 days	 post-graft.	 The	 fixed	 part	 of	 the	 model	 included	variables	 corresponding	 to	 the	 number	 of	 days	 post-graft	 and	 the	 different	 groups.	Interaction	terms	were	built	into	the	model.	Random	intercept	and	random	slope	were	included	 to	 take	 into	 account	 the	 time	 effect.	 The	 coefficients	 of	 the	 model	 were	
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estimated	by	maximum	likelihood	and	considered	significant	at	the	0.05	level.	Survival	rates	 were	 estimated	 using	 the	 Kaplan-Meier	 method	 from	 the	 date	 of	 the	 xenograft	until	 the	 date	when	 the	 tumor	 reached	 a	 volume	of	 1,600	mm3.	 Survival	 curves	were	compared	using	the	log-rank	test.	Statistical	analyses	were	carried	out	using	the	STATA	11.0	software	(StataCorp,	College	Station,	TX).		
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Table	S1	:	scFv2-Fc antibody formats classic pharmacokinetic constants 
	
mouse	phenotype	 mAb	 AUC	(mg.h.mL-1)	 CL	(mL.h-1)	
WT	 H7-Fc	 4.0	[3.3-5.2]	 0.98	[0.93-1.02]		 Irr-Fc	 16,1	[13.0–18.6]	 0.40	[0.36-0.43]	
FcRn	KO	 H7-Fc	 2.4	[1.3–4.0]	 3.30	[3.13-3.38]		 Irr-Fc	 3.3	[2.5–4.4]	 1.31	[1.27-1.35]	
AUC,	Area	Under	the	Curve	calculated	from	day	0	to	day	21,	CL,	serum	clearance;		numbers	in	brackets	
represent	maxima	and	minima	within	the	groups	of	10	mice.	Irr-Fc,	irrelevant	scFv2-Fc.			In	the	WT	background,	H7-Fc	binding	to	mouse	TfR1	decreases	the	AUC	and	increase	CL	compared	to	the	non	specific	counterpart	format.	AUC	of	the	irrelevant	scFv2-Fc	drastically	decreases	and	its	CL	increases	in	the	FcRnKO	background	because	the	antibody	is	not	protected	by	the	FcRn.	The	results	obtained	for	the	H7-Fc,	where	the	AUC	slightly	decreases	and	the	CL	strongly	increases	in	the	FcRnKO	background,	could	indicate	that,	since	FcRn	and	TfR1	colocalize	in	the	recycling	intracellular	trafficking	pathway,	the	binding	of	H7-Fc	to	TfR1	is	enhanced	in	the	absence	of	FcRn	through	limitation	of	steric	hindrance	that	occurs	I	case	of	double	binding.	This	remains	to	be	confirmed	by	further	investigations.			
	
	
Supplementary	figure	legends:	
	
Figure	S1:	Setting	up	of	the	holo-Tf	cell	internalization	test	(A,	 B)	 Raji	 cells	 were	 incubated	 at	 37°C	 or	 4°C	 (to	 allow	 or	 not	 internalization,	respectively)	with	 500	 nM	 holo-Tf	 conjugated	 to	 Alexa-488	 (holo-Tf-A488)	 in	 culture	medium	for	the	indicated	times.	Cells	were	then	washed	with	PBS,	incubated	or	not	with	NaCl-glycine	buffer	(50	mM	glycine	pH	2.8,	500	mM	NaCl)	at	4°C	for	10min,	then	washed	again	 with	 PBS	 to	 remove	 surface-bound	 holo-Tf-A488,	 and	 cell	 fluorescence	 was	measured	 by	 FACS.	 Total,	 fluorescence	 in	 cells	 without	 glycine	 step;	 intracellular,	fluorescence	 in	 cells	 with	 glycine	 step.	 Fluorescence	 increased	 from	 1	 to	 3h	 and	was	more	 than	 95%	 intracellular;	 therefore,	 the	 glycine	 incubation	 step	 was	 omitted	 in	further	 experiments.	 The	 cell	mean	 fluorescence	 intensity	 (MFI)	was	 calculated	 using	the	Flow	Jo	Version	10.1r7	software.	(C)	Raji	cells	were	incubated	with	500	nM	holo-Tf-
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A488	 together	with	 increasing	 concentrations	 of	 unconjugated	holo-Tf	 at	 37°C	 for	 3h.	Increasing	 concentrations	 of	 unconjugated	holo-Tf	 reduced	 fluorescence	 accumulation	(IC50	 =	 580	 nM)	 in	 a	 dose-dependent	 manner,	 showing	 the	 specificity	 of	 the	 holo-Tf	internalization	test.		
Figure	 S2:	 SPR	 analysis	 of	 H7-Fc	 and	 H7-IgG1	 interactions	 with	 recombinant	
human	TfR1	and	competition	with	holo-Tf	(A,B)	 Various	 concentrations	 (0.25-32	 nM)	 of	 homodimeric	 human	 recombinant	 TfR1	were	injected	on	H7-Fc	or	H7-IgG1	captured	on	immobilized	anti-human-Fc	IgG.	The	KD	values,	 taking	 into	 account	 of	 affinity	 and	 avidity	 with	 this	 protocol,	 were	 calculated	using	 a	 steady-state	 fitting	model.	 H7-Fc	 and	 H7-IgG1	 display	 similar	 KD	 (5	 nM).	 (C)	Human	 TfR1	was	 injected	 on	H7-Fc	 or	 H7-IgG1	 immobilized	 onto	 anti-human-Fc	 IgG.	Human	 holo-Tf	 was	 injected	 at	 the	 indicated	 concentrations	 to	 displace	 human	 TfR1.	Higher	 concentrations	 of	 holo-Tf	were	 required	 to	 quantitatively	 release	 human	TfR1	from	H7-Fc	than	from	H7-IgG1,	consistent	with	the	results	obtained	in	the	competition	experiment	for	holo-Tf	internalization	on	cells	of	figure	1D	where	H7-Fc	blocks	holo-Tf	internalization	better	than	H7-IgG1.			
Figure	S3:	3D	modeling	of	the	interaction	of	H7	and	Ba120	with	human	TfR1	
(A)	Modeling	of	the	interaction	of	H7	(red)	and	Ba120	(green)	with	human	TfR1	(grey)	using	their	VH	and	VL	amino	acid	sequences.	Docking	of	both	antibodies	on	human	TfR1	was	done	with	MabTope,11	using	3D	models	of	the	antibodies	and	the	3D	structure	of	the	ectodomain	of	human	TfR1	(PDB:1CX8).12	The	3D	models	of	both	antibodies	were	made	using	Modeller13	and	the	templates	PDB:3F12	for	H7	VH,	PDB:3MA9	for	H7	VL,	3BZH	for	
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Ba120	 VH	 and	 3L7E	 for	 Ba120	 VL	 (NB:	 Ba120	 sequences	were	 determined	 from	 the	original	hybridoma	by	Dr.	Martine	Cerutti,	 CNRS,	 Saint	Christol-Les-Ales,	 France).	(B),	Representation	of	the	interaction	of	human	holo-Tf	(blue,	from	PDB	1SUV)	with	human	TfR1.	This	model	predicts	that	H7	competes	directly	with	holo-Tf	binding,	while	Ba120	and	 holo-Tf	 can	 bind	 to	 TfR1	 at	 the	 same	 time,	 in	 agreement	 with	 the	 in	 vitro	experimental	 data	 (Figure	 2).	 Figures	 were	 prepared	 using	 Pymol	 (The	 PyMOL	Molecular	Graphics	System,	Version	2.0	Schrödinger,	LLC).	MAbTope	is	a	coarse-grained	protein-protein	docking	method,	it	doesn't	use	force	fields,	neither	energy	minimization	and	there's	no	solvent.	MAbTope	uses	HEX	for	docking	poses	generation.	HEX	generates	about	 10^8	 poses.	 The	 top-500	 HEX	 poses	 are	 then	 reranked	 using	 different	 scoring	functions,	of	which	one	is	learnt	on	two	datasets	of	protein-protein	complexes	of	known	structures.	We	have	shown	that	on	a	benchmark	of	129	antibody-antigen	complexes	the	top-30	 ranked	conformations	 correctly	define	 the	epitope,	 and	 that	 in	80%	cases,	 one	near-native	docking	pose	is	present	 in	the	top-30.	For	the	figure,	one	docking	pose	for	each	antibody	has	been	manually	chosen	within	the	top-30.	Thus,	there	is	no	guaranty	that	 the	orientation	of	 the	antibody	relative	 to	 the	 target	 is	 correct,	however	 the	pose	correctly	defines	the	epitope	on	the	TfR1.			
Figure	 S4:	 Variation	 of	 intracellular	 iron	 levels	 in	 the	 Bp3	 and	 the	 Im9	 B-
lymphoma	cell	lines	upon	H7	treatment.		The	 same	 protocol	 than	 Figure	 3B	was	 applied.	 Results	 are	 expressed	 as	 the	 %	 of	change	in	the	fluorescence	relative	to	non	treated	cells	(NT).	In	Bp3	and	Im9	cell	lines,	H7	induced	only	low	soluble	iron	decrease	compared	to	ERY	or	Raji	cell	lines	(see	Figure	
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3B)	and	Ba120	induced	an	increase	in	soluble	iron	levels,	in	agreement	with	its	ability	to	accelerate	holo-Tf	uptake	mediated	by	TfR1	(see	figure	2A,	left	panel).	
	
	
Figure	 S5:	 Comparison	 of	 H7-IgG1,	 Ba120	 and	 human-holo-Tf	 binding	 to	 native	
human	TfR1	at	different	pH	values	The	protocol	described	in	(A)	was	used	to	study	H7-IgG1	binding	to	TfR1	at	different	pH	values,	 similar	 to	 those	 encountered	 during	 physiological	 TfR1	 internalization	 and	recycling	 after	holo-Tf	 binding.	The	 experiment	was	performed	at	 4°C.	Raji	 cells	were	incubated	 with	 anti-TfR1	 antibodies	 (10	 µg/mL)	 or	 human	 holo-Tf	 conjugated	 to	Alexa488	(500	nM)	at	pH	7	 for	1h.	Unbound	antibodies	or	holo-Tf	were	eliminated	by	washing	at	pH	7,	and	then	cells	were	incubated	at	a	given	pH	(from	7	to	5),	to	mimic	the	conditions	 within	 endosomes	 after	 internalization	 (1	 h	 at	 4°C).	 A	 final	 wash	 was	performed	at	pH	7,	to	mimic	the	conditions	after	TfR1	recycling	at	the	cell	surface.	FITC-conjugated	anti-human	or	mouse	IgG	secondary	antibodies	were	used	to	detect	by	FACS	the	 remaining	 bound	 antibodies	 after	 these	 steps.	 (B)	 Results	 are	 expressed	 as	 the	percentage	of	 the	Mean	Fluorescent	 Intensity	(MFI)	relative	to	 the	MFI	of	cells	kept	at	pH	 7	 for	 the	 entire	 experiment.	 As	 expected,	 holo-Tf	 binding	 decreased	 at	 lower	 pH,	because	of	the	loss	of	Fe3+	at	low	pH	and	the	reduced	affinity	of	apo-Tf	at	pH	7.	(C)	The	iron	content	of	holo-Tf	at	various	pH	values	was	monitored	by	taking	advantage	of	the	fact	 that	holo-Tf,	but	not	apo-Tf,	displays	an	absorption	peak	at	460	nm.14	Holo-Tf	(10	µM)	was	resuspended	in	buffer	at	various	pH.	Results	are	expressed	as	the	ratio	of	the	sample	 absorbance	 at	 460	 nm	 normalized	 to	 the	 standard	 protein	 concentration	obtained	at	280	nm.				
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Figure	 S6.	 Biodistribution	 of	 the	 cross-reactive	 anti-TfR1	 H7	 scFv2-Fc	 (H7-Fc)	
antibody	in	mice	with	tumors	The	four	nude	mice	bearing	ERY-1	tumors	that	received	one	i.v.	injection	of	a	mixture	of	
125I-labeled	H7-Fc	 and	 131I-labeled	 irrelevant	 scFv2-Fc	used	 in	Figure	4	were	 killed	 at	48h	post-injection,	 and	 the	 radioactivity	 in	all	organs	and	 tissues	was	quantified	as	 in	
Figure	4.	Results	are	expressed	as	the	%	of	the	injected	dose	(ID)	per	g	(%ID/g).	H7-Fc	accumulated	in	the	tumor.		
Figure	S7.	ADCC	on	BxPC3	and	CFPAC	cells	using	the	anti-TfR1	H7	scFv2-Fc	and	full	
length	IgG1	antibodies	ADCC	was	evaluated	in	live	BxPC3	or	CFPAC	cells	(both	derived	from	a	pancreatic	ductal	adenocarcinoma)	with	 the	 same	protocol	 used	 for	Raji	 cells	 in	Figure	5.	 Briefly,	 cells	were	stained	with	 the	 fluorescent	dye	PKH-67,	and	 the	day	after	were	 incubated	with	H7-Fc	 or	 H7-IgG1,	 or	 an	 irrelevant	 scFv2-Fc	 antibody	 (0.2	 or	 1	 µg/mL	 final	concentration)	 for	 30min.	 Then,	 freshly	 prepared	 PBMC	 (Effector/Target	 ratio	 =	 50)	were	 added	 for	 3h.	 Cells	were	 then	 collected	 and	 stained	with	 the	 7-AAD	 fluorescent	dye.	 The	 percentage	 of	 dead	 cells	 (7AAD+)	 cells	 among	 the	 target	 PKH-67+	 cells	 was	evaluated	 by	 FACS	 analysis.	 The	 H7-IgG1	 antibody	 was	 more	 efficient	 than	 H7-Fc	 to	mediate	ADCC	of	BxPC3	and	CFPAC	cells,	as	already	observed	in	Raji	cells	(Figure	5).			
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Figure S1: Setting up of the holo-Tf cell internalization test 
(A, B) Raji cells were incubated at 37°C or 4°C (to allow or not internalization, respectively) with 
500 nM holo-Tf conjugated to Alexa-488 (holo-Tf-A488) in culture medium for the indicated times. 
Cells were then washed with PBS, incubated or not with NaCl-glycine buffer (50 mM glycine pH 
2.8, 500 mM NaCl) at 4°C for 10min, then washed again with PBS to remove surface-bound holo-
Tf-A488, and cell fluorescence was measured by FACS. Total, fluorescence in cells without glycine 
step; intracellular, fluorescence in cells with glycine step. Fluorescence increased from 1 to 3h and 
was more than 95% intracellular; therefore, the glycine incubation step was omitted in further 
experiments. The cell mean fluorescence intensity (MFI) was calculated using the Flow Jo Version 
10.1r7 software. (C) Raji cells were incubated with 500 nM holo-Tf-A488 together with increasing 
concentrations of unconjugated holo-Tf at 37°C for 3h. Increasing concentrations of unconjugated 
holo-Tf reduced fluorescence accumulation (IC50 = 580 nM) in a dose-dependent manner, showing 
the specificity of the holo-Tf internalization test. 
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Figure S2: SPR analysis of H7-Fc and H7-IgG1 interactions with recombinant human TfR1 
and competition with holo-Tf 
(A,B) Various concentrations (0.25-32 nM) of homodimeric human recombinant TfR1 were 
injected on H7-Fc or H7-IgG1 captured on immobilized anti-human-Fc IgG. The KD values, 
taking into account of affinity and avidity with this protocol, were calculated using a steady-state 
fitting model. H7-Fc and H7-IgG1 display similar KD (5 nM). (C) Human TfR1 was injected on 
H7-Fc or H7-IgG1 immobilized onto anti-human-Fc IgG. Human holo-Tf was injected at the 
indicated concentrations to displace human TfR1. Higher concentrations of holo-Tf were required 
to quantitatively release human TfR1 from H7-Fc than from H7-IgG1, consistent with the results 
obtained in the competition experiment for holo-Tf internalization on cells of figure 1D where H7-
Fc blocks holo-Tf internalization better than H7-IgG1.  
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Figure	S3:	3D	modeling	of	the	interacHon	of	H7	and	Ba120	with	human	TfR1	
(A)	Modeling	of	the	interac0on	of	H7	(red)	and	Ba120	(green)	with	human	TfR1	(grey)	using	their	
VH	 and	 VL	 amino	 acid	 sequences.	 Docking	 of	 both	 an0bodies	 on	 human	 TfR1	 was	 done	 with	
MabTope,11	using	3D	models	of	the	an0bodies	and	the	3D	structure	of	the	ectodomain	of	human	
TfR1	 (PDB:1CX8).12	 The	 3D	 models	 of	 both	 an0bodies	 were	 made	 using	 Modeller13	 and	 the	
templates	PDB:3F12	 for	H7	VH,	PDB:3MA9	 for	H7	VL,	3BZH	 for	Ba120	VH	and	3L7E	 for	Ba120	VL	
(NB:	Ba120	sequences	were	determined	from	the	original	hybridoma	by	Dr.	Mar0ne	CeruU,	CNRS,	
Saint	Christol-Les-Ales,	France).	(B),	Representa0on	of	the	interac0on	of	human	holo-Tf	(blue,	from	
PDB	1SUV)	with	human	TfR1.	This	model	predicts	that	H7	competes	directly	with	holo-Tf	binding,	
while	 Ba120	 and	 holo-Tf	 can	 bind	 to	 TfR1	 at	 the	 same	 0me,	 in	 agreement	 with	 the	 in	 vitro	
experimental	data	(Figure	2).	Figures	were	prepared	using	Pymol	(The	PyMOL	Molecular	Graphics	
System,	 Version	 2.0	 Schrödinger,	 LLC).	 MAbTope	 is	 a	 coarse-grained	 protein-protein	 docking	
method,	 it	doesn't	use	force	ﬁelds,	neither	energy	minimiza0on	and	there's	no	solvent.	MAbTope	
uses	HEX	for	docking	poses	genera0on.	HEX	generates	about	10^8	poses.	The	top-500	HEX	poses	
are	 then	 reranked	 using	 diﬀerent	 scoring	 func0ons,	 of	 which	 one	 is	 learnt	 on	 two	 datasets	 of	
protein-protein	 complexes	 of	 known	 structures.	 We	 have	 shown	 that	 on	 a	 benchmark	 of	 129	
an0body-an0gen	complexes	the	top-30	ranked	conforma0ons	correctly	deﬁne	the	epitope,	and	that	
in	80%	cases,	one	near-na0ve	docking	pose	 is	present	 in	 the	 top-30.	 For	 the	ﬁgure,	one	docking	
pose	for	each	an0body	has	been	manually	chosen	within	the	top-30.	Thus,	there	is	no	guaranty	that	
the	orienta0on	of	the	an0body	rela0ve	to	the	target	is	correct,	however	the	pose	correctly	deﬁnes	
the	epitope	on	the	TfR1.	
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Figure S4: Variation of intracellular soluble iron levels in the Bp3 and the Im9 B-
lymphoma cell lines upon H7 treatment.  
The same protocol than Figure 3B was applied. Results are expressed as the % of change in the 
fluorescence relative to non treated cells (NT). In Bp3 and Im9 cell lines, H7 induced only low 
soluble iron decrease compared to ERY or Raji cell lines (see Figure 3B) and Ba120 induced an 
increase in soluble iron levels, in agreement with its ability to accelerate holo-Tf uptake 
mediated by TfR1 (see figure 2A, left panel). 
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Figure S5: Comparison of H7-IgG1, Ba120 and human-holo-Tf binding to native human TfR1 
at different pH values 
The protocol described in (A) was used to study H7-IgG1 binding to TfR1 at different pH values, 
similar to those encountered during physiological TfR1 internalization and recycling after holo-Tf 
binding. The experiment was performed at 4°C. Raji cells were incubated with anti-TfR1 antibodies 
(10 µg/mL) or human holo-Tf conjugated to Alexa488 (500 nM) at pH 7 for 1h. Unbound antibodies 
or holo-Tf were eliminated by washing at pH 7, and then cells were incubated at a given pH (from 7 
to 5), to mimic the conditions within endosomes after internalization (1 h at 4°C). A final wash was 
performed at pH 7, to mimic the conditions after TfR1 recycling at the cell surface. FITC-conjugated 
anti-human or mouse IgG secondary antibodies were used to detect by FACS the remaining bound 
antibodies after these steps. (B) Results are expressed as the percentage of the Mean Fluorescent 
Intensity (MFI) relative to the MFI of cells kept at pH 7 for the entire experiment. As expected, holo-
Tf binding decreased at lower pH, because of the loss of Fe3+ at low pH and the reduced affinity of 
apo-Tf at pH 7. (C) The iron content of holo-Tf at various pH values was monitored by taking 
advantage of the fact that holo-Tf, but not apo-Tf, displays an absorption peak at 460 nm.14 Holo-Tf 
(10 µM) was resuspended in buffer at various pH. Results are expressed as the ratio of the sample 
absorbance at 460 nm normalized to the standard protein concentration obtained at 280 nm.  
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Figure S6.  Biodistribution of the cross-reactive anti-TfR1 H7 scFv2-Fc (H7-Fc) 
antibody in mice with tumors 
The four nude mice bearing ERY-1 tumors that received one i.v. injection of a mixture of 
125I-labeled H7-Fc and 131I-labeled irrelevant scFv2-Fc used in Figure 4 were killed at 48h 
post-injection, and the radioactivity in all organs and tissues was quantified as in Figure 4. 
Results are expressed as the % of the injected dose (ID) per g (%ID/g). H7-Fc accumulated 
in the tumor. 
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Figure S7. ADCC on BxPC3 and CFPAC cells using the anti-TfR1 H7 scFv2-Fc and full 
length IgG1 antibodies 
ADCC was evaluated in live BxPC3 or CFPAC cells (both derived from a pancreatic ductal 
adenocarcinoma) with the same protocol used for Raji cells in Figure 5. Briefly, cells were 
stained with the fluorescent dye PKH-67, and the day after were incubated with H7-Fc or H7-
IgG1, or an irrelevant scFv2-Fc antibody (0.2 or 1 µg/mL final concentration) for 30min. Then, 
freshly prepared PBMC (Effector/Target ratio = 50) were added for 3h. Cells were then 
collected and stained with the 7-AAD fluorescent dye. The percentage of dead cells (7AAD+) 
cells among the target PKH-67+ cells was evaluated by FACS analysis. The H7-IgG1 antibody 
was more efficient than H7-Fc to mediate ADCC on BxPC3 and CFPAC cells by PBMC, as 
already observed in Raji cells (Figure 5).  
